BioCentury
ARTICLE | Clinical News

JnJ begins Phase IIb trial for mosaic HIV vaccine

December 1, 2017 9:46 PM UTC

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill & Melinda Gates Foundation and NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

The mosaic approach is intended to address many of the different HIV subtypes found globally, unlike previous approaches that focus on viruses from specific geographical areas. The vaccine, Ad26.Mos4.HIV, incorporates immunogens created using genes from multiple HIV subtypes and are delivered via adenovirus serotype 26 (Ad26) viral vectors...